An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Latest Information Update: 25 Dec 2024
At a glance
- Drugs Pegcetacoplan (Primary) ; Pegcetacoplan (Primary)
- Indications Thrombotic microangiopathy
- Focus Pharmacokinetics; Registrational
- Sponsors Swedish Orphan Biovitrum
Most Recent Events
- 19 Dec 2024 Status changed from active, no longer recruiting to completed.
- 05 Nov 2024 According to an Apellis Pharmaceuticals media release, topline data from this study are expected in mid-2025.
- 15 Aug 2024 Planned End Date changed from 9 Jan 2026 to 6 Jan 2025.